The latest from BioStock
» Promore Pharma's CEO about the study results
» Trial leader on Chordate's study on chronic migraine
» New takeover bid for Sensidose
» Redemption of Alzinova's TO3 could add SEK 28 million
» BioInvent reports clinical progress with BI-1206
Read BioStock's newsletter for v.16 here.
Watch the latest episode of in the banner below.
Morning news
Ultimovacs provides update on timeline for readout of the Phase II clinical trial INITIUM of UV1 in malignant melanoma. Read more.
The board of directors of Double Bond Pharmaceutical decides on the issuance of units of approximately SEK 15,8 million with preferential rights for existing shareholders. Read more.
Ascelia Pharma announces that data from the study of hepatic impairment with Orviglance have been accepted as poster presentations at both ESGAR and EASL Scientific Congresses. Read more.
Abera Bioscience reports positive results from toxicological study for pneumococcal vaccine candidate. Read more.
ProstaLund signs distribution agreement for Poland. Read more.
WHAT TO and Xbrane delivers Ximluci in England under contract with NHS. Read more.
Brain+ announces management changes. Read more.
Interim reports:
Alligator Bioscience Lipum Medistim Zenicor Medical Systems Össur
Report presentations:
C-Row EQL Pharma Vibrosense Dynamics
Annual reports:
Coala Life Monivent Senzime Vivesto
Invitations:
Alzinova Cantargia Coegin Pharma Dicot ExpreS2ion Biotech Immunovia Kancera Monivent Neodynamics PExA SensoDetect XP Chemistries Ziccum
Changes in votes and equity:
Communiqués:
AcouBlack Alligator Bioscience Medistim
News since Monday lunch
Alzinova has terminated the agreement with the liquidity guarantor. Read more.
Navamedic published a supplement to the offer document regarding its cash offer to the shareholders of Sensidose. Read more.
EQL Pharma announced an offer to the shareholders of Sensidose. Read more.
Sensidoses board of directors published a statement on the occasion of Navamedics and EQL Pharmas increased public takeover bids. Read more.
Sensidose has been flagged according to Spotlight's regulations after EQL Pharma has increased its holding of shares in the company. Read more.
Phase Holographic announced that the last day for trading in TO3 is April 27. Read more.
Prostatype Genomics published a prospectus in connection with an upcoming rights issue. Read more.
AstraZeneca presented phase III results for eplontersen which showed consistent and sustained improvement in all measures of disease and quality of life over 66 weeks. Read more.
XP Chemistries has received a new order for the product Precise HEAT with an order value of approximately SEK 130. Read more.
ADDvise Group announced that they are carrying out a directed new share issue of approximately SEK 100 million. Read more.
S2Medical has postponed the publication of the annual report. Read more.
Ortivus announced that they have qualified for NHS framework agreement in force MobiMed Life. Read more.
PharmaLundensis announced that April 26 is the last day for trading BTU. Read more.
Bioretec has updated its product pipeline. Read more.
Genmab has appealed its second arbitration award under the license agreement with Janssen. Read more.
Enorama Pharma has postponed its annual general meeting. Read more.
Q-line has initiated cost-saving programs. Read moreThe company has also changed the date for the annual general meeting. Read more.
This morning's price development
Winner: Alligator Bioscience 29,2%, Eevia Health 16,2%, SensoDetect 11,2%, Vivesto 10,5%, Odinwell 9,8%
Förlorare: Double Bond Pharmaceutical -27,5%, Bioservo Technologies -19,7%, Tendo -19,1%, QuiaPEG Pharmaceuticals Hold -15,4%, Clinical Laserthermia Syst -11,4%
Index: OMXS30 2 -241%, Healthcare -0,83%